I'll get that document and obviously respond to that question, perhaps in a follow-up.
What I would want to flag is that we recognize that so much occurs with the drugs as they interact in the real world, as they are used, and we are very committed to having the kind of mechanisms to get the kind of information that helps us and providers--and industry, for that matter--understand that.
That's why we've been working on making it easier for consumers to report. We've added resources significantly in this area. We have a new consumer side effect reporting form, again to try to make it easier. We've strengthened our post-market surveillance capability. We've launched a new website, a new place where people can go and see what has been reported. We have mandatory reporting for industry so that when they become aware of any adverse event or problem, they must report those to us.
In addition, we are working with providers, hospitals, consumers to get their reports. Right now we're working with Accreditation Canada. I'm quite pleased to say that we're working with them to develop standards for their facilities, to in fact incorporate them into the accreditation standards to report to us.
So we are making good progress, and I'm pleased about that.